ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease is a research paper published in Clinical Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 74 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart Lung and Blood Institute
Grant: R01 HL147324
National Institute of Allergy and Infectious Diseases
Grant: P01 AI056299
Intel Corporation
Grant: KD025
Intel Corporation
Grant: KD025-208
Intel Corporation
Grant: KD025-213
National Institutes of Health
Grant: P01 CA142106
NHLBI NIH HHS
Grant: R01 HL118979
NHLBI NIH HHS
Grant: R01 HL056067
NHLBI NIH HHS
Grant: P01 HL158505
Kao Corporation
FWCI
4.97
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China
Additional file 1 of A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China